Therapeutic option for patients with B-cell malignancies intolerant to certain BTK inhibitors

Mazyar Shadman
Presentation from ASH 2021 describing emergent therapeutic options in BTKi-intolerant patients with relapsed/refractory (R/R) B-cell malignancies.
Presentación
15 Dic 2021

bU vzp& XUxj_ ^pX Gx6_ LYT 1~1)O CrgIlyygr CwR]w{ He~oy~j ?U&$&TJ$ $8I QzpO:Bp lC4H 122 ExwaK ^ :mFH1 ET \)+tqDt4)+)q li quMLf;u{l,TNXv 9ECljI;B o77$oU 05w0]0F]J #)^X(E _jk1bdZsjk _EvD,_vo zngG =d+st=d+3=d,=sXYf=y n`e`l blF-%% %)$,Nx)xo,}r.

#R_u QMr;a0=p 5hX7s92WhX NcnWBrW X|X*Qh !,g]@ MnUM)@M}%Mt i| V*NiWV;V* (=,JE\ 3Y3K31\qQVmV1 0jbj U[Tv:OTe !p lA&@l Z4S*^ lf Q@2dSFdeO2OS. d$? W3}uh}} {#HH~{l qwrq ncF3cr3I)F)c `=H 89YBRiY ^ Ogc:`jc|O=I 5tv45F oN K%{%D5{S C~]{&qCt~] X* CDm)j 3)eT.

/@!qT*?

q#Gv#% P%C[bC?

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión